Last reviewed · How we verify

Catabolic Process — Treatment Landscape & Competitive Intelligence

Catabolic Process (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Catabolic Process, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Oxandrin OXANDROLONE Crealta Pharms Llc oxandrolone Androgen receptor 1964-01-01
Oxandrin Oxandrin Par Pharmaceutical, Inc. Androgen receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Catabolic Process
  2. Crealta Pharms Llc · 1 drug in Catabolic Process
  3. Par Pharmaceutical, Inc. · 1 drug in Catabolic Process

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Catabolic Process:

Cite this brief

Drug Landscape (2026). Catabolic Process — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/catabolic-process. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing